The inhibition of FGF-23 activity with burosumab is associated with an increase in renal tubular phosphate reabsorption and the correction of hypophosphatemia in children with X-linked hypophosphatemia, which corresponds to a decrease in the severity of rickets. This evidence concerns the gene FGF23 and X-linked hypophosphatemia.